In the following video, Motley Fool health care bureau chief Brenton Flynn discusses an interesting takeaway from the JPMorgan conference yesterday. While there are already options for investors to invest directly in the diabetes space, one thing that caught his eye was a potential indirect diabetes play, in the form of Dynavax's (NASDAQ:DVAX) hepatitis-B vaccine. While the vaccine is not yet approved, the CDC's Advisory Committee on Immunization Practices recommended in 2011 that all diabetes patients between the ages of 19 and 59 be vaccinated against hepatitis B, which could double or potentially triple Dynavax's existing market opportunity for the vaccine.
Brenton Flynn has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
3 Stocks That Could Put NVIDIA's Returns to Shame
Outperforming the graphics chipmaker won't be easy, but these three stocks have what it takes.
1 Reason Dynavax Technologies Corporation Stock Soared in 2017
Thanks to the FDA approval of its hepatitis B vaccine, Dynavax's shares crushed the broader market in 2017.
3 Growth Stocks to Own in 2018
If you're looking for outstanding growth vehicles to own next year, these three biotech stocks are worth checking out.